Stocks & Investing
Stocks and Investing
Stocks and Investing
Wed, March 13, 2024
[ Wed, Mar 13th 2024
] - WOPRAI
[ Wed, Mar 13th 2024
] - WOPRAI
[ Wed, Mar 13th 2024
] - WOPRAI
[ Wed, Mar 13th 2024
] - WOPRAI
[ Wed, Mar 13th 2024
] - WOPRAI
[ Wed, Mar 13th 2024
] - WOPRAI
[ Wed, Mar 13th 2024
] - WOPRAI
[ Wed, Mar 13th 2024
] - WOPRAI
[ Wed, Mar 13th 2024
] - WOPRAI
[ Wed, Mar 13th 2024
] - WOPRAI
[ Wed, Mar 13th 2024
] - WOPRAI
[ Wed, Mar 13th 2024
] - WOPRAI
[ Wed, Mar 13th 2024
] - WOPRAI
[ Wed, Mar 13th 2024
] - WOPRAI
[ Wed, Mar 13th 2024
] - WOPRAI
[ Wed, Mar 13th 2024
] - WOPRAI
[ Wed, Mar 13th 2024
] - WOPRAI
[ Wed, Mar 13th 2024
] - WOPRAI
[ Wed, Mar 13th 2024
] - WOPRAI
[ Wed, Mar 13th 2024
] - WOPRAI
[ Wed, Mar 13th 2024
] - WOPRAI
[ Wed, Mar 13th 2024
] - WOPRAI
[ Wed, Mar 13th 2024
] - WOPRAI
[ Wed, Mar 13th 2024
] - WOPRAI
[ Wed, Mar 13th 2024
] - WOPRAI
[ Wed, Mar 13th 2024
] - WOPRAI
[ Wed, Mar 13th 2024
] - WOPRAI
Calvin Sternick Maintained (USPH) at Buy with Increased Target to $117 on, Mar 13th, 2024
Calvin Sternick of JP Morgan, Maintained "U.S. Physical Therapy, Inc." (USPH) at Buy with Increased Target from $99 to $117 on, Mar 13th, 2024.
Calvin has made no other calls on USPH in the last 4 months.
There is 1 other peer that has a rating on USPH. Out of the 1 peers that are also analyzing USPH, 0 agree with Calvin's Rating of Hold.
This is the rating of the analyst that currently disagrees with Calvin
- Michael Petusky of "Barrington Research" Maintained at Buy with Increased Target to $122 on, Friday, March 1st, 2024
